Results 31 to 40 of about 63,359 (335)
Clinical Cancer Research, 2022 Purpose: To evaluate efficacy and safety of venetoclax + azacitidine among treatment-naïve patients with IDH1/2-mutant (mut) acute myeloid leukemia (AML).
D. Pollyea +15 more
semanticscholar +1 more source
Proteogenomic characterization of cholangiocarcinoma
Hepatology, EarlyView., 2022 Proteogenomic characterization of cholangiocarcinoma with therapeutic strategies Abstract Background and Aims Cholangiocarcinoma (CCA) is a highly heterogeneous cancer with limited understanding and few effective therapeutic approaches. We aimed at providing a proteogenomic CCA characterization to inform biological processes and treatment ...
Mengjie Deng +18 more
wiley +1 more source
Brain Sciences, 2020 Glioblastoma is a solid, infiltrating, and the most frequent highly malignant primary brain tumor. Our aim was to find the correlation between sex, age, preoperative Karnofsky performance status (KPS), presenting with seizures, and extent of resection ...
Maurizio Salvati +12 more
doaj +1 more source
IDH1‐mutant cancer cells are sensitive to cisplatin and an IDH1‐mutant inhibitor counteracts this sensitivity [PDF]
The FASEB Journal, 2018 IntroductionIsocitrate dehydrogenase 1 (IDH1) is mutated in various types of human cancer and the presence of a mutation is associated with improved responses to irradiation and chemotherapy in solid tumor cells. Mutated IDH1 (IDH1MUT) enzymes consume NADPH to produce D‐2‐hydroxyglutarate (D‐2HG) resulting in a decreased reducing power needed for ...
Khurshed, Mohammed +7 more
openaire +3 more sources
Haematologica, 2020 Mutant IDH1 (mIDH1) inhibitors have shown single-agent activity in relapsed/refractory AML, though most patients eventually relapse. We evaluated the efficacy and molecular mechanism of the combination treatment with azacitidine, which is currently the standard of care in older AML patients, and mIDH1 inhibitor BAY1436032. Both compounds were evaluated
Anuhar Chaturvedi, +17 more
openaire +6 more sources
Allosteric Mutant IDH1 Inhibitors Reveal Mechanisms for IDH1 Mutant and Isoform Selectivity [PDF]
Structure, 2017 Oncogenic IDH1 and IDH2 mutations contribute to cancer via production of R-2-hydroxyglutarate (2-HG). Here, we characterize two structurally distinct mutant- and isoform-selective IDH1 inhibitors that inhibit 2-HG production. Both bind to an allosteric pocket on IDH1, yet shape it differently, highlighting the plasticity of this site.
Julia Dooley +22 more
openaire +3 more sources
Epigenetics, 2020 Mutations in the enzyme isocitrate dehydrogenase 1 (IDH1) lead to metabolic alterations and a sustained formation of 2-hydroxyglutarate (2-HG). 2-HG is an oncometabolite as it inhibits the activity of α-ketoglutarate-dependent dioxygenases such as ten ...
Christian Gerecke +4 more
doaj +1 more source
The Frequency and clinical significance of IDH1 mutations in Chinese acute myeloid leukemia patients. [PDF]
PLoS ONE, 2013 OBJECTIVE: Mutations in the gene encoding isocitrate dehydrogenease 1 (IDH1) occur in various hematopoietic tumors including acute myeloid leukemia (AML), myeloproliferative neoplasms and myelodysplastic syndromes.
Lixun Guan +6 more
doaj +1 more source
Clinical Cancer Research, 2021 Purpose: Lower grade gliomas (LGGs) are malignant brain tumors. Current therapy is associated with short- and long-term toxicity. Progression to higher tumor grade is associated with contrast enhancement on MRI.
I. Mellinghoff +20 more
semanticscholar +1 more source
IDH1 and IDH2: Not Your Typical Oncogenes [PDF]
Cancer Cell, 2010 Oncogenes usually increase their normal function when activated. However, seemingly oncogenic mutations in IDH1 and IDH2 reduce their native enzyme activity. In this issue of Cancer Cell, Ward et al. pin down a neomorphic enzyme activity as a possible oncogenic function for these alterations.
D. Williams Parsons +2 more
openaire +3 more sources